Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

accelerate — Glargine Opportunity Builds Up For Biocon • Source: Alamy

Supplies of Biocon, Ltd.’s partnered interchangeable insulin glargine biosimilar (branded Semglee) buoyed earnings momentum for the Indian firm’s biosimilars business in the fiscal third quarter, with “significant uptake” in store in view of several commercial arrangements already in place in the US.

Biocon Biologics’ deputy CEO Shreehas Tambe highlighted recent gains made by partner Viatris Inc. for the product, which received...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

31 Jul 2025

• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

31 Jul 2025

• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

31 Jul 2025

• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

31 Jul 2025

• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

31 Jul 2025

• By Mandy Jackson

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.